SCHEMBL6489573

SCHEMBL6489573

CCOC(=O)c1ccnc(OCc2cc(C)c3nc(C)n(Cc4ncc(C(F)(F)F)cc4Cl)c3c2)c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.39
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP2D6 P10635 1/20 0.37
KMT2A Q03164 5/20 0.36
MEN1 O00255 4/20 0.36
POLB P06746 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34
F11 P03951 1/20 0.34
MRGPRX4 Q96LA9 2/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488333 0.92 MRGPRX4 (0.43) CYP1A2CYP3A4CYP2C19CYP2D6KMT2A
SCHEMBL6490408 0.85 JMJD6 (0.41) CYP1A2CYP3A4CYP2C19CYP2D6KMT2A
SCHEMBL6487814 0.85 MEN1 (0.43) MAOBCYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL6498752 0.82 MEN1 (0.41) MAOBCYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL6490180 0.81 LMNA (0.41) CYP1A2CYP3A4CYP2C19CYP2D6KMT2A
SCHEMBL6488312 0.81 P2RX3 (0.42) CYP1A2CYP3A4CYP2C19CYP2D6KMT2A
SCHEMBL6491606 0.81 MRGPRX4 (0.41) CYP1A2CYP3A4CYP2C19CYP2D6KMT2A
SCHEMBL7197594 0.81 MRGPRX4 (0.39) CYP1A2CYP3A4CYP2C19CYP2D6KMT2A
SCHEMBL6489988 0.79 DCTPP1 (0.40) CYP1A2CYP3A4CYP2C19CYP2D6KMT2A
SCHEMBL6497968 0.78 CYP1A2 (0.39) CYP1A2CYP3A4CYP2C19CYP2D6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD MAOB 1631/4885CYP1A2 247/4885CYP3A4 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.